Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 194

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 194
---
 | ​                   |   6,140,000 | ​ | ​    |           — |
| Noncash redemption of Series A convertible preferred stock                       | ​ | ​                   |   1,195,743 | ​ | ​    |           — |
| Accrued Series A convertible Preferred payments payable                          | ​ | ​                   |   2,047,583 | ​ | ​    |           — |
| Accretion of Series A convertible preferred stock to redemption value            | ​ | ​                   |   4,829,755 | ​ | ​    |           — |
| Accrual of Series convertible preferred stock dividends                          | ​ | ​                   |     556,733 | ​ | ​    |           — |
| Reclass of warrant liability upon warrant modification                           | ​ | ​                   |   7,570,000 | ​ | ​    |           — |

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-7

<div align='center'>**PETROS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**</div>

**Unless the context otherwise indicates, references in these Notes to the accompanying financial statements to “we,” “us,” “our” and “the Company” refer to Petros Pharmaceuticals, Inc. (a Delaware corporation) and subsidiaries.**

1) Nature of Operations, Basis of Presentation, and Liquidity Nature of Operations and Basis of Presentation Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the “Merger Agreement”), by and between Petros, Neurotrope, Inc. Petros consists of wholly owned subsidiaries, Metuchen, Neurotrope, Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). We are engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which we have licensed from Vivus, Inc. (“Vivus”). Petros also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. Petros is committed to the goal